𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era

✍ Scribed by Corey Cutler; Joseph H. Antin


Book ID
107540339
Publisher
Current Science Inc.
Year
2006
Tongue
English
Weight
199 KB
Volume
1
Category
Article
ISSN
1558-8211

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Novel tyrosine kinase inhibitor therapy
✍ Elias Jabbour; Jorge Cortes; Hagop Kantarjian; Sergio Giralt; Borje S. Andersson πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKI